TY  - JOUR
AU  - Acker, Fabian
AU  - Reck, Martin
AU  - Martin, Daniel
AU  - Rieken, Stefan
AU  - Heinzen, Sophie
AU  - Rost, Maximilian
AU  - Aguinarte, Lukas
AU  - Schulte, Hanna
AU  - Serve, Hubert
AU  - Oellerich, Thomas
AU  - Sebastian, Martin
AU  - Althoff, Friederike C
TI  - Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis.
JO  - European journal of cancer
VL  - 218
SN  - 0959-8049
CY  - Amsterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-00279
SP  - 115266
PY  - 2025
AB  - In patients with unresectable, stage III non-small cell lung cancer (NSCLC), durvalumab maintenance after concurrent chemoradiotherapy (cCRT) was shown to improve survival over placebo. As subgroup analyses indicated better outcomes with earlier start of durvalumab, several trials evaluated concomitant checkpoint inhibition (CPI) with cCRT. However, this may introduce an increased risk of treatment-related pulmonary toxicity.We conducted a systematic review and meta-analysis of clinical trials of combined cCRT plus CPI followed by CPI maintenance in patients with stage III NSCLC. Endpoints included incidence of pneumonitis by any cause, objective response rate (ORR), progression-free (PFS), and overall survival (OS).A total of 7 trials comprising 653 patients were included. In trials of single-agent CPI with cCRT, pneumonitis occurred in 33 
KW  - Checkpoint inhibitor (Other)
KW  - Chemoradiotherapy (Other)
KW  - Locally advanced (Other)
KW  - Meta-analysis (Other)
KW  - NSCLC (Other)
KW  - Stage III (Other)
KW  - Systematic review (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39893747
DO  - DOI:10.1016/j.ejca.2025.115266
UR  - https://inrepo02.dkfz.de/record/298423
ER  -